Chile: These 2 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Chile
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Chile: These 2 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Chile Patent 2,010,000,775
Patent Title: Compuestos derivados de 3-bencil benceno sustituidos por glucopiranosil; composicion farmaceutica; combinacion farmacuetica que comprende a dichos compuestos; y su uso para el tratamiento o la prevencion de enfermedades metabolicas tales como diabetes, entre otras (divisional de la solicitud 566-05).
This drug has two hundred and twenty-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Chile Patent 2,010,000,775
Patent Title: Compuestos derivados de 3-bencil benceno sustituidos por glucopiranosil; composicion farmaceutica; combinacion farmacuetica que comprende a dichos compuestos; y su uso para el tratamiento o la prevencion de enfermedades metabolicas tales como diabetes, entre otras (divisional de la solicitud 566-05).
This drug has one hundred and ninety-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
